Cholera Vaccination Reaction
4
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
10 treatments under study, led by Osprtthc Cholera Conjugate Vaccine Cohort A
Research Leaders
7 sponsors active, led by International Vaccine Institute
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants
Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults
Extended Dose Intervals With Oral Cholera Vaccine in Cameroon
Research Network
Common Treatments
- Osprtthc Cholera Conjugate Vaccine Cohort A1
- Duochol1
- Osprtthc Cholera Conjugate Vaccine With Aluminum Phosphate Adjuvant Cohort A1
- Osprtthc Cholera Conjugate Vaccine Cohort C1
- Osprtthc Cholera Conjugate Vaccine With Aluminum Phosphate Adjuvant Cohort B1
Active Sponsors
- International Vaccine Institute2
- Meilleur Accès aux Soins de Santé (M.A. Santé)1
- Massachusetts General Hospital1
- Centre for Infectious Disease Research in Zambia1
- EuBiologics Co.,Ltd1
Top Investigators
Johns Hopkins Bloomberg School of Public Health
International Vaccine Institute
+82 2 8811 274
Related Conditions
- Adverse Reaction To Cholera Vaccine1